U.S. Markets open in 4 hrs 54 mins

EnteroMedics Inc. (ETRM)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
4.62+0.27 (+6.21%)
At close: 4:00PM EDT
People also watch
IDXGPULMBIOCXGTIGLBS
  • What's happening post-hours?
  • Nothing to get excited about as they will sell it off as always......it wont hold!
  • yeah because america is fat!
  • On July 25 , 2017, EnteroMedics Inc. (the “Company”) entered into a Collaboration Agreement with Galvani Bioelectronics Limited (“Galvani”). Under the Collaboration Agreement, EnteroMedics will modify its vBloc System for use in pre-clinical research by Galvani. EnteroMedics will receive payments for its development work and supply under this agreement. EnteroMedics will retain all rights, title, and ownership in the intellectual property for the new device, which will be licensed to Galvani. Galvani has been granted a right of first negotiation for the potential exclusive or non-exclusive supply by EnteroMedics of the developed device, exercisable at Galvani’s election.

    EnteroMedics believes that this collaboration is an example of opportunities that may exist to leverage the company’s intellectual property portfolio and custom development services to provide third party sales and licensing opportunities.

    Galvani is a joint venture between GlaxoSmithKline and Verily Life Sciences (an Alphabet company) that was established in 2016 to enable the research, development and commercialization of bioelectronic medicines.
  • My buy order for 1000 more shares was filled at $4.37 at 3:46 pm yesterday... added 684 the day before at $4.45. Nice to finally make a buy BEFORE a spike for once that wasn't expected... "GO FAT PEOPLE"..!!
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

  • Going big today
  • $5.22 [+.87] AFTER HRS.
    Lets Rock !
  • Hhmmm... the answer of my long wait has come. There's really GOD. Thanks and good luck!
  • $10/share is reasonable.
  • My guess is that ETRM is due for a pullback in the short-run. I started receiving notifications from awe-SOME-stocks the other week and so far they have presented interesting new trade ideas.
  • Poised to run.
  • Here she comes
  • Monster MicroCaps Alert to ETRM shareholders - $BLGO in early part of very big move. Shares up 35% in last week getting ready for several major very bullish events in short term:

    1.    CupriDyne Clean industrial odor control sales exploding.  In under 60 days, 3 of the Top 10 Waste Industry Giants have signed Master Supply Agreements with BioLargo and word on street is that CupriDyne works so much better than the competition that it is going to dominate all odor control. There are over 1,000,000 industrial facilities with serious unmet needs for odor control. CupriDyne destined to be multi-billion-dollar product very soon.
    2.    BioLargo Clyra Medical Division ready to file 510k with FDA this month for revolutionary low cost advanced wound care products.  Clyra has figured out how to use iodine as the most powerful known disinfectant ever known against even resistant strains, and make it completely non toxic.  This is a revolutionary product that is also likely to take a big bite out of the 10 billion dollar wound care industry.
    3.    BioLargo’s AOS SYSTEM is the biggest breakthrough in water treatment in history. A commercial beta Prototype is being unveiled and showcased this August at the University of Alberta.  The market is well over $800 Billion for the AOS SYSTEM.

    Monster MicroCaps BLGO 2017YE Price target - $5.00
    Monster MicroCaps BLGO 2018YE Price target - $18.00

    http://biolargo.blogspot.com/2017/06/2017-is-break-through-year-dennis.html?m=1

    "2017 is a Break-Through Year" - Dennis Calvert's LD Micro Presentation on June 6, 2017
    BioLargo President and CEO Dennis Calvert presented the company's growth strategy at the 7th annual LD Micro Invitational on June 6th, 2017 ...
    biolargo.blogspot.com
  • This message board gonna get busy soon again. More interesting stuffs are hovering. Good luck!
  • Gonna be a good day for etrm owner s
  • EnteroMedics participation in a major international obesity conference in Mexico should give exposure to this
    company. *** Conference runs from June 28th (today) through July 1st.
    Comments anyone?
  • $10 is a reasonable price
  • Monster MicroCaps SPECIAL ALERT to ETRM shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market.
    https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
    finance.yahoo.com
  • Do you know it costs 100% to borrow this stock???? Anyone have a clue to #$%$ is going on????